Robert J. Motzer, MD, on Research Areas of Focus in Renal Cell Carcinoma

Video

The medical oncologist at Memorial Sloan Kettering Cancer Center discussed areas of research in renal cell carcinoma that he thinks should be further explored.

In an interview with CancerNetwork®, Robert J. Motzer, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, highlighted areas of research within renal cell carcinoma (RCC) which he believes should be studied further.

Transcription:

I think we’ve made tremendous headway with [immuno-oncology] combinations. I’m hoping that some of the drugs with novel mechanism of actions like [belzutifan; MK-6482], will bear fruit and advance our therapeutic options. And I think the other area that really needs to be explored is a better look and a deep dive into the underlying tumor biology and why some patients respond to 1 medication and some respond to another. Are there different targets that we can identify within the tumors? That’'\s an area now that really needs to be explored.

Recent Videos
Based on its mechanism of action, anito-cel may cause fewer instances of cytokine release syndrome and delayed toxicities vs other therapies.
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Sonia Jain, PhD, stated that depatuxizumab mafodotin, ABBV-221, and ABBV-321 were 3 of the most prominent ADCs in EGFR-amplified glioblastoma.
Skin toxicities are common with targeted therapies for GI malignancies but can be remedied by preventative measures and a collaboration with dermatology.
Related Content